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ABSTRACT 
Background 
The short and long-term relationship between hyperglycemia and PTH level among 
patients suffering from both diabetes type 2 and vitamin D deficiency were evaluated.  
Methods 
This was a cross sectional study performed at Dubai Diabetes Center, UAE. To 
demonstrate the relationship between hyperglycemia and PTH level, subjects with type 2 
diabetes and vitamin D deficiency (124 adults) were divided into 4 groups based on their 
FPG and HbA1c levels.  
 Results 
 Mean vitamin D and PTH levels among subjects with HbA1c≤7% (53 mmol/mol) were 
14.05 ng/ml and 19.51pg/ml respectively. On the other hand, mean vitamin D and PTH 
levels among subjects with HbA1c≥10% (86 mmol/mol) were significantly lower at 
11.77 ng/ml and 17.75pg/ml respectively. The product of vitamin D and PTH among 
subjects with an HbA1c≤7% (53 mmol/mol) was 250.380, compared with only 197.710 
among subjects with HbA1c≥10 (86 mmol/mol). Regression analysis for subjects older 
than 50 years shows a significant negative effect of HbA1c on the PTH level. Mean 
calcium level among subjects with HbA1c≤7% (53 mmol/mol) was 8.80 mg/dl compared 
with 8.94 mg/dl when HbA1c is ≥10% (86 mmol/mol) with no statistical difference. 
Although high FPG was associated with a lower PTH level, such association was not 
statistically significant. 
Conclusions 
Chronic hyperglycemia, as assessed by A1C level, is associated with a significantly 
attenuated PTH responsiveness to vitamin D deficiency without a significant change in 
calcium level. On the other hand, there was no significant association between FPG and 
PTH level.  _________________________________________________________________________________
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1. Introduction 
Vitamin D deficiency and diabetes represent two of the most common metabolic health problems 
in the United States and the whole world. It is estimated that 387 million people had diabetes in 
2014 and that by 2030 this may rise well above half a billion cases (1). The number of adults 
with diagnosed diabetes in the United States nearly quadrupled, from 5.5 million to 21.3 million 
during the period from 1980 through 2012 (2). Among adults, about 1.7 million new cases of 
diabetes are diagnosed each year. If this trend continues, as many as 1 out of every 3 adults in the 
United States could have diabetes by 2050 (2). Meanwhile, several reviews have found a global 
prevalence of vitamin D deficiency. In 2008, it was estimated that one billion individuals have 
vitamin D deficiency (25OH Vitamin D <20 ng/ml) (3). Despite the adequate UVB radiation in 
low latitude  
geographic locations, vitamin D deficiency was still found to be a very common health issue (4). 
Similarly, the prevalence of vitamin D deficiency is still quite high in industrialized countries 
despite the implementation of vitamin D fortification programs for many years (5-8). Although 
the association between diabetes and vitamin D deficiency has been proved (9), it is still unclear 
whether it is a cause and effect relationship or if vitamin D deficiency is merely a consequence 
of obesity. Since hypovitaminosis D causes a compensatory increase in the secretion of PTH; 
calcium levels usually remain within the normal limits. PTH restores eucalcemia through its 
effects on the kidney and bone. At the kidney level, PTH increases the conversion of calcidiol to 
calcitriol by 1alpha-hydroxylase. Furthermore, PTH increases the renal distal tubule reabsorption 
of calcium, and excretion of phosphorus. The bone effect of PTH is mediated through the PTH 
direct stimulatory effect of the osteoclasts and the indirect effects of calcitriol in enhancing 
further osteoclast activation and bone resorption (10). In addition to its effects on the kidney and 
bone, the increased levels of calcitriol stimulate the active intestinal absorption of calcium and 
phosphorus (10). Several factors have been demonstrated to modify the serum PTH response to 
low circulating 25(OH) vitamin D. Magnesium deﬁciency was found to play an important role in 
functional hypoparathyroidism (11). In men with vitamin D deficiency, it was demonstrated that 
higher levels of IGF1 and testosterone are associated with a lower PTH level whilst greater BMI 
is linked to a higher PTH level. On the other hand, for women suffering from vitamin D 
deficiency, the combined effect of smoking, BMI and cystatin C appears to explain 36.2% of the 
variability in the PTH level. Smoking has the greatest association with reduced PTH levels, 
explaining 20.8% of the variability in the PTH level (12). Circadian variations in PTH, (13) and 
the variations in Vitamin D binding protein (14) and its impact on the free Vitamin D levels are 
some other examples of these factors. 
  
Although the effect of endocrinopathy on hyperglycemia was evaluated extensively, there is little 
data on the effect of hyperglycemia on the function of the endocrine system. Since vitamin 
D deficiency is very common among patients with diabetes, the relationship 
between hyperglycemia and the PTH level may answer many questions related to calcium and 
bone metabolism. If hyperglycemia will enhance PTH production, the higher levels of 
PTH may increase bone turnover (15) and possibly increase fracture risk (16, 17). On the other 
hand, if hyperglycemia will reduce the PTH levels, it may result in clinically 
significant hypocalcemia. The main objective of this study is to evaluate the relationship 
between hyperglycemia and the parathyroid hormone level among patients suffering from 
vitamin D deficiency and type 2 diabetes.  
 
2. Methods 
This is a cross sectional study consisting of 124 consecutive patients. All subjects are adults with 
type 2 diabetes mellitus and vitamin D deficiency (defined as 25(OH) vitamin D level of less 
than 30 ng/ml) who came to Dubai Diabetes Center for the management of their diabetes during 
the period between February1
st
 to April30th, 2012. All participants were United Arab Emirates 
citizens who live in the Emirate of Dubai (latitude 25 N). The exclusion criteria were tobacco 
smoking, alcohol intake, renal impairment (eGFR<70 mL/min/1.73 m
2
), abnormal urinary 
albumin excretion (urine albumin/ creatinine ratio >30 mg/g), pregnancy and the use of any 
drugs which can influence bone metabolism such as thyroid hormones, steroids, products 
containing vitamin D or its derivatives, calcium, magnesium, lithium, anti-convulsants, sex 
hormones and medications used for the treatment of osteoporosis. All enrolled patients met with 
a registered dietician and were put on a nutritional plan according to the American Diabetes 
Association nutrition guidelines (18). A daily intake of 1,000–1,500 mg of calcium was 
recommended. 
Body weight and height were measured with the subject barefoot and wearing light clothing and 
used to calculate the body mass index (BMI). All participants were required to fast for at least 8 
h before having the following lab tests: HbA1c (%), serum creatinine (mg/dl), BUN(mg/dl), 
serum calcium (mg/dl), albumin (g/dl), serum phosphate (mg/dl), alkaline phosphatase ALP 
(IU/L), magnesium (mmol/L), total (both 25(OH)D2 and 25(OH)D3 25 hydroxyvitamin D) 
(ng/ml), intact PTH (pg/ml) and urine calcium and creatinine. Calcium was corrected to albumin 
level by using the following formula: serum calcium+0.8 (4-serum albumin). Venous blood 
sampling was performed using a tourniquet to help locate and define peripheral veins to achieve 
successful and safe venipuncture. As prolonged venous stasis may affect the accuracy of calcium 
level measurement, the application of a tourniquet did not exceed one minute. 
The HbA1c determination was based on the turbidimetric inhibition immunoassay (TINIA) for 
hemolyzed whole blood. Quality control procedure was performed according to HITACHI 912 
Analyzer Calibration Procedure PD-RBIO-HT-002.  Albumin, Magnesium, Phosphorus 
(Phosphate-PO4) and Alkaline Phosphatase measurement was made on Hitachi 912 analyzer by 
Colorimetric assay with endpoint method. External Quality Control is carried out every two 
weeks through Bio-Rad Clinical Chemistry Control. Serum calcium was assayed by a method 
  
according to Schwarzenbach with o-cresolphthalein complexone. Intact PTH (Parathyroid 
Hormone) determination was measured by using RIA technique on the Gamma Counter Wizard 
1470. The Intact PTH present in the standards, controls or the samples is first incubated with the 
incubation buffer for 60 minutes with continuous shaking. This will allow the PTH to be 
captured to the anti- PTH coating the tube. After washing with the wash buffer, the iodine 125 
labeled anti- PTH antibodies are added. Another 60-minute incubation with continuous shaking. 
Washing with the wash buffer is then performed. The radioactivity bound to the tube is 
proportional to the concentration of PTH present in the standards, controls and sample. The kit 
was obtained from Bioosource. Internal quality control is assayed with every run and external 
quality control is performed every two weeks by Bio- Rad Set 2 assayed hormone control. 
25(OH) Vitamin D total determination was based on using RIA technique on the Gamma 
Counter Wizard 1470. A fixed amount of 125I labeled 25OH vitamin D competes with the 25OH 
vitamin D2 and 25OH vitamin D3 from treated samples for affixed amount of a specific 
monoclonal antibody site immobilized to inner surface of tubes. After 2 hours of incubation, 
aspiration steps terminate reaction. The tube washed twice and read on gamma counter. The kit 
is from Diaosource. Internal quality control is assayed with every run and external quality 
control is performed every two weeks by Bio- Rad. The RIA method intra assay %CV 
coefficient of variation is 4.8%.  
 
2.1 Statistical Analysis  
This study included (n=124) diabetic patients through a convenience (non-probability) sampling 
method from one of the largest diabetes centers in the city of Dubai, United Arab Emirates. After 
records with missing data (14%), and/or univariate outliers (3%) were excluded, the sample size 
became (106). No multivariate outliers were detected. Results of evaluation of assumptions of 
normality, multicollinearity and homogeneity of variance were satisfactory on the target 
variables (HbA1c, FPG, PTH, 25(OH) vitamin D, cCa, and Mg). After the subjects with missing 
data and outliers were excluded, the sample size was still greater than what was required for 
regression test criteria (106)>50+8*(5 IVs) for five independent variables (19).   
To demonstrate the relationship between chronic hyperglycemia and the PTH level, subjects 
were divided into 4 groups based on their HbA1c levels. HbA1c≤ 7.0% (53 mmol/mol) (n=36) 
was considered as a good control, HbA1c 7.1-8.4% (54-68 mmol/mol) (n=42) as an inadequate 
control, HbA1c 8.5-9.9% (69-85 mmol/mol) (n=14) as a poor control and HbA1c≥10% (86 
mmol/mol) (n=14) as a very poor control.  On the other hand, to demonstrate the relationship 
between FPG and the PTH level, subjects were divided into 4 groups based on their FPG levels. 
FPG ≤130 mg/dl (n=37) was considered as a good control, FPG 131-170 mg/dl (n=38) as 
inadequate control, FPG 171-200 mg/dl (n=11) as a poor control and FPG >200 mg/dl (n=19) as 
a very poor control. Number of subjects older than 50 years of age was 58 (27 males, and 31 
females) while the number of those ≤50 years old was 48 (20 males, and 28 females). The PTH 
level was specifically compared between subjects who were older than 50 years of age with their 
younger counterparts.  
  
Means trend analysis, simple linear regression, and a generalized linear model were used to answer the 
question whether HbA1c level affects the PTH response to vitamin D deficiency. On the other hand, 
generalized estimated equation (GEE) was used to answer the question whether magnesium level plays 
any role in the PTH response to vitamin D deficiency. Although GEE statistical method requires a 
large number of clusters to produce consistent estimates, we do believe we have fulfilled this 
requirement with our sample size and the fact that missing values are less than 5%. The GEE 
model in this study was built by using the following criteria: [1] the repeated subject is the 
patient-ID number; [2] the sample size is 106 cluster “patients”. This number was found to be 
sufficient to study 5-12 exploratory variables (19). The sample size (106) was enough to run a 
regression model with a power percentage of 80%, alpha=0.05 and beta=0.20.  Clusters with 
missing values were 14; [3] since the dependent variable (PTH) satisfied normality, the identity 
linked function was used; [4] the 25(OH) vitamin D (coded as VitD) and the HbA1c were the 
independent variables [5] the correlation structure “Exchangeable” was used. 
Means trend analysis, simple linear regression, and a generalized linear model were used to 
answer the question whether HbA1c level is associated with a different response of the PTH to 
vitamin D deficiency. A generalized estimated equation (GEE) was used to answer three research 
points (1) whether magnesium level plays any role in the PTH response to vitamin D deficiency; 
(2) whether PTH is influenced by the product (interaction) of HbA1c and vitamin D 
(HbA1c*VitD) and (3) whether the regression relationship between PTH and both of HbA1c and 
vitamin D is different among patients who are older than 50 years of age compared with those of 
a younger age.  
2.2 Ethical approval 
Medical Research Committee of Dubai Health Authority had approved the study and an 
informed consent was obtained from all patients. 
 
3. Results 
3.1 Patients 
In total, 47 male and 59 female adults were studied. The median age of all enrolled subjects was 
55 years with a range between 34.8 and 76.2 years. Subjects’ characteristics are shown in Table 
(1).   
3.2 PTH response to vitamin D deficiency at different HbA1c levels 
Figure (1) shows the mean levels of 25(OH) vitamin D, PTH, cCa, Mg and PO4 among the four 
HbA1c and FPG groups. There was a significant (P=0.028) inverse correlation between 25(OH) 
vitamin D level and HbA1c in both genders. Although 25(OH) vitamin D was also inversely 
correlated with the fasting plasma glucose (FPG), the inverse correlation between HbA1c and 
25(OH) vitamin D was much stronger. The relationship between parathyroid hormone and 
25(OH) vitamin D with each HbA1c group shown in Figure 2 is significant. The moderate 
correlation value was 0.56 for subjects with an HbA1c of ≤ 7 (53 mmo/mol), 0.2 for subjects 
with an HbA1c of 7.1-8.4 (54-68 mmol/mol), 0.46 for subjects with an HbA1c of 8.5-9.9% (69-
  
85 mmol/mol) and 0.53 for subjects with an HbA1c of ≥10 (86 mmol/mol) (P<0.005). Serum 
25(OH) vitamin D concentrations ranged between 4.0-21.30 ng/ml (laboratory reference values: 
30-100 ng/dl) with a mean value being 13.35 ng/ml. On the other hand, plasma levels of intact 
PTH ranged from 5.0-40.0 pg/ml (laboratory reference values: 6.2- 29.0 pg/ml) with a mean 
value being 17.67 pg/ml. Although PTH levels continued to increase with lower levels of 
25(OH) vitamin D, our data showed that for the same level of 25(OH) vitamin D, PTH response 
is attenuated among patients with higher HbA1c levels. The data summarized in Figure (2) 
shows that hyperglycemia with higher HbA1c levels among patients with diabetes type 2 is 
associated with an attenuated PTH responsiveness to vitamin D deficiency. Although higher 
PTH levels are associated with lower levels of 25(OH) vitamin D, the negative slope becomes 
less steep when HbA1c is higher. In contrast, regression analysis did not show a significant 
association between FPG and the responsiveness of PTH to vitamin D deficiency.  
Our results show that there is a significant association between PTH level and the interaction (the 
product) of HbA1c and 25(OH) vitamin D with a negative coefficient value of (-0.064, p<0.002). 
While the interaction (product) value of 25(OH) vitamin D and PTH among subjects with 
HbA1c≤7% (53 mmo/mol) was 250.380, it was only 197.710 among subjects with HbA1c≥10 
(86 mmol/mol) (-0.064, p<0.002). 
 
3.3 Vitamin D and HbA1c levels may predict PTH level 
 
 The GEE analysis provided the following findings:  
(1) Although the mean trend analysis (Fig 1) shows that a higher HbA1c is associated with a 
lower Mg level, the change in Mg level was not statistically significant.  
(2) PTH was shown to be predicted from the HbA1c interaction with vitamin D, the following 
model predicts PTH level for all subjects:  
PTH= 24.341 - 0.064 HbA1c(%)*VitD, p<0.002. 
(3) Age is an important factor to predict the PTH level. The following model is able 
to more accurately predict the PTH level for subjects who are older than 50 years of age:  
PTH= 34.153 – 0.680 VitD – 2.523 HbA1c (%), p<0.003.  
This relationship clearly shows the negative effects of both HbA1c and (25) OH vitamin D on 
the dependent variable PTH with negative slopes of (-0.68) and (-2.523) respectively. This 
obvious relationship was not seen among subjects who are younger than 50 years. 
 
4. Discussion 
In this cross sectional study, we showed that chronic hyperglycemia is associated with a 
lower parathyroid hormone level among patients with vitamin D deficiency and type 2 diabetes. 
Few studies have been conducted to examine the relationship between hyperglycemia and the 
parathyroid hormone (PTH) secretion. Nguyen et al showed that hyperglycemia due to glucose 
load induced an increase in calcium excretion among healthy subjects following oral glucose 
tolerance test (OGTT) with 75g carbohydrate (20). Venkataraman et al showed that serum 
calcium, Magnesium and phosphorus values declined significantly in normal neonates after an 
oral glucose load, and the decline in serum calcium was significantly correlated with the amount 
of glucose ingested. They showed that the above changes were associated with a significant 
  
compensatory rise in serum PTH but no significant change in the ionized calcium level (21). On 
the other hand, other studies have demonstrated a suppressive effect of acute hyperglycemia on 
the parathyroid hormone production with a decline in serum calcium and an increase in urinary 
calcium excretion (22).  
Secondary hyperparathyroidism is a well-known consequence of low 25(OH) vitamin D level. 
Since blunted PTH level was not thoroughly evaluated, only few factors were found to attenuate 
the responsiveness of PTH to low vitamin D levels. Due to the fact that low magnesium levels 
may attenuate the PTH secretion, magnesium level was specifically evaluated in our available 
data. Although it was slightly lower (mean=1.84) among patients with higher HbA1c levels 
(>7.0), the difference in the magnesium level was not statistically significant. In our study, 
we could simply replicate the well-known hyperbolic inverse association between 25(OH) 
vitamin D and PTH levels for all HbA1c and FPG levels through curve estimation regression 
analysis (Fig. 2). Since there is still little literature on the relationship between 25(OH) vitamin D 
and glycemic control, we studied this correlation among all enrolled patients. Our data is clearly 
showing that chronic hyperglycemia is associated with a lower parathyroid hormone level among 
patients with type 2 diabetes and vitamin D deficiency. In fact, the results among the groups that 
have the largest number of subjects (the groups of A1c of less than 7 and 7.1-8.4) show more 
obvious difference in the slope (i.e. the slope becomes much less steep when HbA1c is higher). 
Furthermore, the difference in the PTH mean and R2 value between these two groups is more 
pronounced than any other groups (PTH mean dropped from 19.51 among the group of HbA1c 
of less than 7 to 16.03 among the group of HbA1c of 7.1-8.4) and the R2 value dropped 
from 0.32 among the group of HbA1c of less than 7 to 0.04 among the group of HbA1c of 7.1-
8.4). Therefore, the results among subjects of these two groups show much larger differences 
than any other groups. The slope value of the 7.1-8.4 group is out of the expected trend range 
probably because the variance is high and homoscedastic in this group. This is most likely due to 
the fact that the HbA1c was falling in the middle between the good and poor control. For the 
sake of simplicity, the only dependent variable that was included in this simple regression 
model was vitamin D level. The influence of other factors such as age, gender, duration of 
diabetes was not included.  
 
Since there is little literature on the association between hyperglycemia and the PTH level, the 
study was designed to evaluate the relationship between both FPG and HbA1c and the PTH level 
among patients with vitamin D deficiency and type 2diabetes. In our study, we showed that 
higher HbA1c levels are associated with an attenuated PTH responsiveness to vitamin D 
deficiency. Although high FPG was associated with a reduced PTH levels, the results were not 
statistically significant. Interestingly, the groups of A1c of less than 7 and 7.1-8.4 have at least 
one subject with the 25-hydroxyvitamin D of about 5 ng/ml with the most robust PTH 
response. Despite the fact that the duration of diabetes and degree of hyperglycemia have 
consistently been identified as predictors of microvascular complications, multiple studies have 
shown that many patients with diabetes may escape complications. The Medalist Study is one of 
these example studies that suggest the presence of certain protective factors against developing 
the complications. This assumption was based on the data of individuals with extreme duration 
of type 1 diabetes who are either protected from or have markedly slower progression of diabetic 
retinopathy (23). The significant number of complication free diabetic patients may strongly 
  
indicate that there are protective molecular, physiologic or genetic mechanisms that protect 
against the toxic effects of hyperglycemia. Figure 2 clearly shows that there are still some 
subjects with a very good PTH responsiveness to vitamin D deficiency despite the high HbA1c 
level. Nevertheless, the magnitude of the highest two PTH levels among each of the four HbA1c 
groups was still decreasing with the increasing levels of HbA1c. Furthermore, like any other 
complications of diabetes, there are other potential risk factors that may play an important role in 
the pathogenesis of "attenuated PTH responsiveness to hypovitaminosis D" among patients 
with type 2 diabetes. Such factors may include duration of diabetes, hypertension, 
hyperlipidemia, genetic risk factors and the presence of certain inflammatory bio-markers. Since 
our study did not evaluate the impact of any of these potential risk factors on the PTH 
responsiveness, the data in figure 2 is only representing a simple regression model (i.e. only one 
dependent variable "vitamin D level" was included) for simplicity. Because there was no 
association between the demographics of BMI and gender and the PTH level, it was concluded 
that the selection criteria had achieved homogeneity among all subjects and therefore, 
demographic adjustment was excluded from these models. Interestingly, corrected calcium level 
did not significantly change despite the fact that the higher HbA1c level was associated with a 
significant decrease in the PTH level among patients with vitamin D deficiency. Moreover, 
neither the phosphate nor the urine calcium (urine calcium/urine creatinine ratio) showed a 
significant change among the four groups of HbA1c. Interestingly, the chronic hyperglycemia-
associated attenuation of PTH secretion was only seen among subjects (males and females) who 
are older than 50 years of age. Since we do not have a clear explanation for this association, we 
believe that the most likely reason is the fact that older people are more likely to have their 
diabetes for a longer period of time with a longer exposure to chronic hyperglycemia.  
Nevertheless, few in vitro studies have shown a direct suppressive effect of high concentration of 
glucose on PTH secretion from cultured bovine parathyroid cells (24). Although it was shown 
that an oral glucose load induced hyperglycemia promotes a significant decline in serum PTH in 
postmenopausal women (25), to our knowledge, no data are available showing the relationship 
between chronic hyperglycemia and PTH or calcium levels among patients suffering from type 2 
diabetes. Since hyperglycemia is usually associated with higher levels of insulin and other 
endocrine changes, such as abnormalities of gonadal and hypophyseal axis, the exact 
pathophysiological effects of hyperglycemia on the PTH production and bone metabolism 
remain complex and would need more investigations. The reduction in bone resorption after 
intravenous administration of insulin (26) is just an example of these biochemical bone changes 
that may occur after developing hyperglycemia. Surprisingly, calcium levels did not change 
significantly among subjects with a higher HbA1c despite the fact that their PTH level was 
significantly lower. This finding is consistent with many other observational studies that have 
shown a normal calcium level among patients suffering from diabetes and vitamin D deficiency 
(27). Although it was initially thought that diabetic patients may have a primary disturbance of 
bone metabolism with a negative net calcium balance (28), Ishida et al. reported that type 2 
diabetics exhibited higher serum parathyroid hormone related peptide (PTHrP) levels than 
control subjects (29). They proposed that elevated PTHrP levels might play a compensatory role 
in calcium homeostasis in diabetic patients. Additional evidence was further obtained by the 
  
group of Suzuki et al. (30) who found a significant positive correlation between calcemia and 
PTHrP in type 2 diabetic patients. They speculated, therefore, that the increased levels of serum 
PTHrP in type 2 diabetic patients could compensate for the decreased PTH levels. Because their 
data had shown a positive correlation of PTHrP with glucose levels, they concluded that PTHrP 
is related to the presence of type 2 diabetes and not to the patient’s obesity and hormonal status. 
Obviously, our data does not include the PTHrP level to allow us draw any conclusion on the 
role of PTHrP level among subjects with higher HbA1c, low vitamin D and attenuated PTH 
levels who still have a normal calcium level. However, the possibility of higher PTHrP level 
among these patients cannot be excluded especially with the fact that the urinary calcium or 
serum phosphorus levels among the different HbA1c groups are not significantly different. Since 
PTHrP has a similar effect to the PTH on the distal renal tubules, the possibility that higher 
levels of PTHrP are stimulating the reabsorption of calcium in the distal renal tubules through 
binding to the PTH receptors needs to be further evaluated.  
To the best of our knowledge, this is the only study that has evaluated the relationship between 
hyperglycemia and PTH responsiveness to vitamin D deficiency. Nevertheless, the current study 
had a few limitations. First, this was a cross-sectional study, and we recommend long-term 
prospective studies to evaluate any possible cause-and-effect relationships. Second, obtaining a 
larger sample size would be more representative of the population. Third, we did not include 
people of different ethnic backgrounds to determine whether the risk and degree of these 
complications vary according to ethnicity. Fourth, we did not include the duration of diabetes 
and the medications used for its treatment in our data. Fifth, PTHrP level was not measured 
among enrolled subjects.  
 
5. Conclusion 
Our findings indicate that chronic hyperglycemia is associated with a significantly attenuated 
PTH responsiveness to vitamin D deficiency without causing hypocalcemia. On the other hand, 
FPG is not associated with a significant decrease in PTH level. Interestingly, the chronic 
hyperglycemia-associated attenuation of PTH secretion was only seen among subjects (males 
and females) who are older than 50 years of age.  
Due to the fact that potential bone effects of low PTH levels among patients with diabetes have 
not been elucidated thoroughly, further studies addressing the possible adverse (or beneficial) 
effects of low PTH with its altered calcium homeostasis are warranted.   
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Fig 1: Means trend by HbA1c and FPG levels. 
 
 
Abbreviations: A1c, glycosylated Hemoglobin Type A1c; VitD, 25 Hydroxy-Vitamin D. 
   
 
  
VitD PTH cCa Mg PO4 
A1C ≤ 7.0 13.69 19.51 8.81 1.9 3.52 
A1C 7.1-8.4 13.99 16.03 8.9 1.84 3.72 
A1C 8.5-9.9 12.16 17.78 8.85 1.9 3.49 
A1C ≥10 11.77 17.75 8.94 1.77 3.48 
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Fig 2: PTH concentrations Regression on Vitamin D at different levels of HbA1c 
Although the PTH level increases with lower levels of 25(OH) vitamin D, the negative slope 
becomes less steep when HbA1c is higher. 
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Figure 3:  
(PTH x Vitamin D) Product significantly decreases with higher HbA1c levels.  
 
 
 
 
  
  
Table 1 Descriptive Statistics  
 Male (n=46) Female (n=60) 
Variable Mean 
Std 
Dev 
Lower 
95% 
Upper 
95% 
Mean 
Std 
Dev 
Lower 
95% 
Upper 
95% 
CL 
for 
Mean 
CL 
for 
Mean 
CL 
for 
Mean 
CL 
for 
Mean 
Age (y) 54.98 10.86 51.63 58.32 51.32 12.2 48.14 54.5 
Body weight 
(Kg) 
104.9 11.47 101.4 108.3 105.6 13.12 102.2 109 
Height (m) 1.67 0.08 1.65 1.69 1.57 0.07 1.55 1.58 
BMI (kg/m2) 30.56 4.97 29.07 32.06 33.5 6.26 31.88 35.11 
FPG (mg/dL) 153.1 49.04 138.5 167.6 156.8 52.71 143.2 170.4 
Albumin (g/dL) 4.52 0.32 4.43 4.62 4.29 0.34 4.2 4.37 
cCa (mg/dL) 8.8 0.41 8.68 8.92 8.93 0.42 8.82 9.04 
sCa (mg/dL) 9.22 0.39 9.1 9.33 9.16 0.42 9.05 9.27 
PO4, (mg/dL) 3.45 0.43 3.32 3.57 3.71 0.59 3.55 3.86 
Mg (mg/dL) 1.92 0.18 1.86 1.97 1.82 0.19 1.77 1.86 
ALP (IU/L) 65.59 16.95 60.55 70.62 75.2 22.5 69.39 81.01 
BUN (mg/dL) 30.89 8.36 28.38 33.4 24.38 8.08 22.21 26.54 
HbA1c (%) 7.7 1.91 7.13 8.27 7.99 1.47 7.61 8.37 
Intact PTH 
(pg/mL) 
16.29 6.69 14.3 18.28 18.73 7.62 16.76 20.7 
25(OH) VitD 
(ng/mL) 
14.88 4.12 13.66 16.11 12.18 3.98 11.15 13.2 
RUCa 
mg/G creatinine 
7.51 5.22 5.45 9.58 6.09 4.01 4.36 7.82 
 
 
  
  
Highlights 
 
Chronic hyperglycemia is associated with a significantly attenuated PTH responsiveness to 
vitamin D deficiency without causing hypocalcemia. 
Acute hyperglycemia is not associated with a significant decrease in PTH levels among patients 
suffering from type 2 diabetes and vitamin D deficiency.  
 
